← Oncology Approval Tracker

FDA DECISION ·

Imbruvica oral suspension

ibrutinib · Pharmacyclics / AbbVie

FDA approvalNew formulationChronic graft-versus-host disease
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Oral suspension for adults and children age one or older with chronic GVHD after failure of at least one systemic therapy line.

LAMPGEN ANALYSIS

Why it matters

The liquid formulation provides a labeled option for younger patients and patients who need liquid administration.

What research teams should watch

Check formulation strength, administration device, and age- and body-size-based dosing instructions.

PRIMARY RECORDS

Sources